Key result
Combined invasive strategy cuts ischemia or new scars ~71% vs medical therapy alone in asymptomatic diabetes.
Why the study?
Does MPS screening and subsequent targeted therapy improve outcomes in asymptomatic patients with type 2 diabetes at high coronary risk?
RCT (n=400)
randomized
Yes
Does MPS screening and subsequent targeted therapy improve outcomes in asymptomatic patients with type 2 diabetes at high coronary risk?
Absolute Event Rate: 15.8% vs 54.3%
p-value: p=<0.001
In asymptomatic high-risk patients with type 2 diabetes, an abnormal screening MPS identifies a subgroup with a significantly higher risk of CAD progression and MACE despite therapy, though an invasive strategy may reduce scintigraphic progression.
Hypothesis-generating for combined invasive-medical strategy in asymptomatic diabetics with abnormal MPS; larger randomized trials needed before practice change.
OBJECTIVES: The purpose of this study was to evaluate prevalence, progression, treatment, and outcome of silent coronary artery disease (CAD) in asymptomatic patients with diabetes (DM) at high coronary risk. BACKGROUND: Despite the close association of diabetes and CAD, general CAD screening in asymptomatic patients with DM is discouraged even though outcome data in patients at high coronary risk are lacking. METHODS: Prospective multicenter outcome study-with a pilot randomized treatment substudy. The study comprised 400 asymptomatic patients with DM (type 2) without history or symptoms of CAD at high CAD risk. They underwent clinical evaluation and myocardial perfusion single-photon emission computed tomography (MPS) at baseline and after 2 years. Patients with normal MPS received usual care; those with abnormal MPS received medical or combined invasive and medical management. RESULTS: An abnormal MPS was found in 87 of 400 patients (22%). In patients with normal MPS, MACE occurred in 2.9% and ischemia or new scar in 3.2%. Patients with abnormal MPS had more MACE (9.8%; hazard ratio: 3.44; 95% confidence interval [CI]: 1.32 to 8.95; p = 0.011) and ischemia or new scar (34.2%; odds ratio: 15.91; 95% CI: 7.24 to 38.03; p < 0.001) despite therapy, resulting in "overt or silent CAD progression" of 35.6% versus 4.6% (odds ratio: 11.53; 95% CI: 5.63 to 24.70; p < 0.001). Patients with abnormal MPS randomized to medical versus invasive-medical strategies had similar event rates (p = 0.215), but more ischemic or new scar findings (54.3% vs. 15.8%; p < 0.001). CONCLUSIONS: High-risk asymptomatic patients with DM and normal MPS (78%) have a low rate of first manifestations of CAD. Patients with abnormal MPS at baseline (22%) have a 7-fold higher rate of progression to "overt or silent CAD," despite therapy. Randomized patients' outcomes suggest that a combined invasive and medical strategy for silent CAD may reduce scintigraphic but not symptomatic CAD progression versus medical therapy alone. (Trial of Invasive versus Medical therapy of Early coronary artery disease in Diabetes Mellitus ISRCTN87953632).
No takes yet. Share an insight, caveat, or question.
Zellweger et al. (2014) conducted an RCT in Asymptomatic diabetes mellitus (type 2) at high coronary risk (n=400). Combined invasive and medical management vs. Medical management alone was evaluated on Ischemic or new scar findings (p=<0.001). A combined invasive and medical strategy reduced ischemic or new scar findings compared to medical therapy alone in asymptomatic patients with diabetes and abnormal MPS (15.8% vs 54.3%; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: